Pibrentasvir
Pibrentasvir
Pibrentasvir (pronounced as pib-ren-tas-vir) is an antiviral medication used in the treatment of Hepatitis C. It is often used in combination with another medication, glecaprevir, to form a complete treatment regimen.
Etymology
The name "Pibrentasvir" is derived from parts of the words 'Picomolar inhibitor', 'HCV', 'NS5A', 'resistance', and 'antiviral'.
Usage
Pibrentasvir is used in combination with glecaprevir to treat chronic hepatitis C, including genotypes 1-6. The combination is marketed under the brand name Mavyret in the United States and Maviret in the European Union.
Mechanism of Action
Pibrentasvir is an NS5A inhibitor, which means it works by blocking a specific protein that the hepatitis C virus needs to replicate. This stops the virus from multiplying, which lowers the amount of hepatitis C virus in the body.
Side Effects
Common side effects of pibrentasvir include headache, fatigue, and nausea. More serious side effects can include reactivation of hepatitis B in those who have previously been infected with this virus.
Related Terms
External links
- Medical encyclopedia article on Pibrentasvir
- Wikipedia's article - Pibrentasvir
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski